CClinicalTrials.gg
CompletedNCT03029299Updated Sep 25, 2017

Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting

An interventional study of FilmArray RP EZ in Respiratory Tract Infections, sponsored by BioFire Diagnostics, LLC. Completed at 1 site in United States. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by BioFire Diagnostics, LLC · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
Up to 100 Years
Sex
All
01

Study summary

BioFire Diagnostics, LLC (BioFire; a bioMerieux company), has developed a multiplexed molecular-based in vitro diagnostic platform for infectious disease testing known as the FilmArray. The FilmArray Respiratory Panel (RP) EZ is a test designed for use with the FilmArray 2.0 EZ Configuration instrument that identifies common bacterial and viral microorganisms associated with respiratory tract infections from a nasopharyngeal swab (NPS) specimen collected in viral transport media (VTM). The RP EZ was granted CLIA-waived classification by the FDA in October 2016 and is the first highly-multiplexed molecular test to receive this designation.

The purpose of this study is to measure patient outcomes following implementation of the RP EZ test and to also gather data about physician office workflow and user interactions with the device. These data will be used to understand how the adoption of such tests may influence patient care in the CLIA-waived setting.

Read the detailed description

The FilmArray RP EZ may offer improvements over conventional CLIA-waived testing for respiratory infections. Molecular-based testing provides increased sensitivity and specificity relative to current clinical reference methods and multiplexed panels offer a greater breadth of organism identification and diagnostic yield than is available using standard methods available in the CLIA-waived setting. Because of these attributes, the results from this test have the potential to enable clinicians to more accurately diagnose and treat respiratory illness.

It is hypothesized that the sensitive, specific, and comprehensive results provided by FilmArray RP EZ will allow clinicians to more rapidly diagnose respiratory illness and implement appropriate therapy, as well as provide subjects with appropriate expectations about their course of illness.

This interventional clinical trial that will be initiated during the 2016-2017 respiratory illness season to measure the utility of FilmArray RP EZ when implemented in an outpatient care setting. At least three different outpatient or urgent care clinics within the UCLA Health system will be selected for participation. Subjects will be randomized into two groups within each site. The control group will receive standard of care according to the subject's provider's determination. The intervention group will receive testing with FilmArray RP EZ.

Outcome measures will include (but are not limited to) total healthcare costs, antimicrobial prescription rates, timeliness, and appropriateness of therapy, clinician attitudes towards laboratory test capabilities, and subject satisfaction with their healthcare encounter.

As specimens will be collected specifically for this research study, written informed consent, assent, and/or parental permission will be obtained from all study participants.

02

Conditions studied

  • Respiratory Tract Infections
03

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat, runny nose, myalgia, headache, chills, or fatigue.
  • Subject provides written informed consent/assent/parental permission
  • Willing and able to provide NPS specimen

Exclusion criteria

Exclusion Criteria:

  • Subject is unable to provide consent/assent/parental permission
  • Children whose legal guardian is not available to give permission
  • Unable/unwilling to provide NPS specimen
  • Non-English speaking
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • No intervention
    Control

    Subjects receive standard of care testing as determined by the clinician.

  • Experimental
    Intervention

    Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)

    Device: FilmArray RP EZ

Interventions

  • DeviceFilmArray RP EZ

    Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician

05

What researchers measure

Primary outcomes

  1. Time duration from initial visit to receipt of appropriate therapy

    Time to appropriate therapy as measured in days compared between intervention and control arms.

    Time frame: through study completion, an average of one year

Secondary outcomes

  1. Satisfaction scores

    Subject and clinician satisfaction with healthcare encounter as measured on 4 point preference scale (highly satisfied, satisfied, dissatisfied, highly dissatisfied) and compared between intervention and control arms

    Time frame: through study completion, an average of one year

  2. Total healthcare costs

    Comparison of total healthcare costs measured in dollars for patients in Control vs Intervention arm

    Time frame: through study completion, an average of one year

06

Study locations

1 site
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03029299
Lead sponsor
BioFire Diagnostics, LLC
Collaborators
University of California, Los Angeles
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Apr 4, 2017
Primary completion
Sep 15, 2017
Completion
Sep 15, 2017
Last update
Sep 25, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion